Banner_image%252Bcrop.jpg
 

A MULTI-FACETED APPROACH TO

understand & CURE GLIOBLASTOMa

The Nathanson Lab focuses on malignant brain tumors, in particular glioblastoma (GBM) – one of the most lethal of all cancers. We take an interdisciplinary approach to understand the biology of brain cancer and to develop innovative therapeutics to ultimately improve on patient outcomes

RESEARCH

Biology_small.png

FUNCTIONAL BIOLOGY OF BRAIN CANCER

Cancers, including malignant glioma, have hijacked and rewired many normal cellular functional processes in order to grow and survive.  These cancer “hallmarks” – as defined by Hanahan and Weinberg (Cell 2011) – include resisting cell death and deregulated metabolism. Notably, reprogramming of these functional pathways in cancers is a direct consequence of aberrant oncogenic signaling emanating from the loss of tumor suppressors and/or mutations in oncogenic drivers. Accordingly, our lab has hypothesized that investigating the interplay between oncogenic signaling and metabolism/cell death pathways can reveal novel therapeutic vulnerabilities.

Drugdev_small.png

DRUG DISCOVERY AND DEVELOPMEnt of brain-penetrant therapies

The effective treatment of brain tumors requires that drugs get into the brain to target the tumor. However, the vast majority of FDA approved drugs do not cross the blood brain barrier (BBB) – a physical barrier that is highly selective for what can cross into the brain. Through collaborations with Dr. Michael Jung (Distinguished Professor of Chemistry, Co-Inventor of two FDA approved drugs for cancer), we have established a drug development program that is focused on synthesizing and testing new, potent and brain-penetrant drugs that specifically target malignant glioma cells.

GliomaPDOX_small.png

Developing Innovative Pre-clinical Models of brain tumors

The translation of therapeutic strategies for treating several malignancies have been hampered by the lack of robust pre-clinical models that accurately reflect the human disease. This is particularly relevant in malignant gliomas, where the genetic and functional properties of conventional cell lines show dramatic divergence from the original patient samples. This has major implications for understanding the biology of these tumors and the development of new therapies. To address this, we have created a novel patient-derived, orthotopic glioma xenograft library (termed GliomaPDOX). This library captures the vast molecular diversity of GBM.

molecular_small.png

MOLECULAR Diagnostics OF BRAIN TUMORS

Although all gliomas originate in the brain, the molecular alterations are often unique between each patient’s tumor. These distinctions can have profound implications for diagnosis and therapeutic response. Our laboratory uses next generation sequencing – including RNAseq and exome sequencing – of patient and GliomaPDOX tumors to precisely define the molecular abnormalities that are driving each glioma. To complement this, we also employ non-invasive molecular imaging, such as positron emission tomography (PET), to examine how imaging can predict tumor response to therapeutics targeting specific molecular alterations in glioma patients and models.

FEATURED PUBLICATIONS

 

Nathanson Lab poster presentation at EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Barcelona, demonstrating ERAS-801 activity in preclinical models of brain metastasis lung cancer.

CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis

Malignant tumors exhibit heterogeneous metabolic reprogramming, hindering the identification of translatable vulnerabilities for metabolism-targeted therapy. How molecular alterations in tumors promote metabolic diversity and distinct targetable dependencies remains poorly defined…

READ FULL ARTICLE

Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors.

The epidermal growth factor receptor (EGFR) is genetically altered in nearly 60% of glioblastoma tumors; however, tyrosine kinase inhibitors (TKIs) against EGFR have failed to show efficacy for patients with these lethal brain tumors…

READ FULL ARTICLE

Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma.

Cross-talk among oncogenic signaling and metabolic pathways may create opportunities for new therapeutic strategies in cancer….

READ FULL ARTICLE

Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA

Single-cell analyses of patient-derived models and clinical samples from glioblastoma patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) demonstrate that tumor cells reversibly up-regulate or suppress mutant EGFR expression…

READ FULL ARTICLE

 
 

Meet Our Team


David Nathanson,

Ph.D. Professor

 

Graduate Student Researchers

Elizabeth Fernandez,

PhD Candidate

Nick Bayley,
PhD Candidate

Jenna Minami,

PhD Candidate

Quincy Okobi,

PhD Candidate

Marissa Pioso,

PhD Candidate

Jennifer Salinas,
PhD Candidate

Dimitri Cadet,

MD-PhD Candidate

Cassidy Andrasz, PhD Candidate

Armon Goshayeshi,

PhD Candidate

Lisa Cha,

MD-PhD Candidate

Tiffany La,

Rotation Student

 

Research Staff

Christopher Tse,

Program Manager

Michael Vigman,

Drug Discovery

Allie Yoon,

Drug Discovery

Amir Borujerdpur, Bioinformatics

Raul Davila,


Model System Development

Ronald Bernal,


Model System Development

Max Johnson,

in vivo Drug Development

Ivan Khoroz,

in vivo Drug Development

Rashmika Kulshrestha,

in vivo Drug Development


Undergraduate Research Assistants

Melody Jiang, Undergraduate Student Researcher

Alanna Lemp, Undergraduate Student Researcher

Marissa Li, Undergraduate Student Researcher

Toby Harris, Undergraduate Student Researcher

Molly McAndrew,

Undergraduate Student Researcher

Sarah Lee,

Undergraduate Student Researcher

Karim Gonzalez,

Undergraduate Student Researcher

Christian Lee,

Undergraduate Student Researcher

Caitlyn Loo,

Undergraduate Student Researcher

Kailyn Kennada,

Undergraduate Student Researcher

Sama Suliman,

Undergraduate Student Researcher

Aliya Sabater,

Undergraduate Student Researcher


LAB NEWS

 

OPEN POSITIONS

 
IMG_1840Edit.jpg

Postdoctoral Researcher

Open position in translational brain cancer research focusing on cell signaling and apoptosis.

CONTACT

Want to learn more or get involved? Contact Us!

UCLA CHS 23-234
650 Charles E Young Dr South
Los Angeles, CA 90036

+1 (310) 825-6006